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Background: Fibromyalgia (FM) is a clinical syndrome characterized by chronic pain and allodynia. The diagnosis of
FM has been one of exclusion as a test to confirm the diagnosis is lacking. Recent data highlight the role of the
immune system in FM. Aberrant expressions of immune mediators, such as cytokines, have been linked to the
pathogenesis and traits of FM. We therefore determined whether cytokine production by immune cells is altered in
FM patients by comparing the cellular responses to mitogenic activators of stimulated blood mononuclear cells of
a large number of patients with FM to those of healthy matched individuals.
Methods: Plasma and peripheral blood mononuclear cells (PBMC) were collected from 110 patients with the
clinical diagnosis of FM and 91 healthy donors. Parallel samples of PBMC were cultured overnight in medium alone
or in the presence of mitogenic activators; PHA or PMA in combination with ionomycin. The cytokine
concentrations of IFN-γ, IL-5, IL-6, IL-8, IL-10, MIP-1β , MCP-1, and MIP1-α in plasma as well as in cultured
supernatants were determined using a multiplex immunoassay using bead array technology.
Results: Cytokine levels of stimulated PBMC cultures of healthy control subjects were significantly increased as
compared to matched non-stimulated PBMC cultures. In contrast, the concentrations of most cytokines were lower
in stimulated samples from patients with FM compared to controls. The decreases of cytokine concentrations in
patients samples ranged from 1.5-fold for MIP-1β to 10.2-fold for IL-6 in PHA challenges. In PMA challenges, we
observed 1.8 to 4-fold decreases in the concentrations of cytokines in patient samples.
Conclusion: The cytokine responses to mitogenic activators of PBMC isolated from patients with FM were
significantly lower than those of healthy individuals, implying that cell-mediated immunity is impaired in FM
patients. This novel cytokine assay reveals unique and valuable immunologic traits, which, when combined with
clinical patterns, can offer a diagnostic methodology in FM.Background
Fibromyalgia (FM) is a chronic pain and fatigue syn-
drome that affects ten to fifteen million adults in the
United States. Patients with FM display diffuse hyper-
algesia (i.e., increased response to painful stimuli) and/or
allodynia (i.e., a heightened sensitivity to stimuli that are
not normally painful). Other clinical manifestations in-
clude debilitating fatigue, sleep disturbance, joint stiff-
ness, cognitive dysfunction and depression. In the past,
this syndrome has been known as fibrositis, nonarticular
rheumatism, the chronic fatigue syndrome, myodys-
neuria, fibromyositis and muscular rheumatism, among
others. The diagnosis of FM is one of exclusion as there* Correspondence: bsgmd@hotmail.com
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reproduction in any medium, provided the orare no specific laboratory tests or radiographic/imaging
studies to confirm this diagnosis. The only physical find-
ing currently used for diagnosis is excess tenderness on
palpation of soft tissues [1-5]. Patients who have been la-
beled with the diagnosis of FM commonly spend years
seeking confirmation of this health problem. The lack of
an objective test to either confirm or rule-out the exist-
ence of FM not infrequently results in some patients
being labeled as neurotic, hypochondrical or emotionally
unstable.
The etiology of FM is not completely understood but
the current hypothesis is that FM arises from interac-
tions between the autonomic central nervous system,
the hypothalamic-pituitary-adrenal axis and the immune
system [6-9]. In the past, FM was considered a rheuma-
tologic disorder based upon the assumption that it is a
type of inflammatory fibro-connective malady. This istd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.






















Psychotherapist Confirmed Diagnosis of Depression 9
* The Caucasian classification was also used if patients identified themselves
as Hispanic.
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autoimmune disorders, such as systemic lupus erythe-
matosus [10,11], Sjogren's Syndrome [12,13], and
rheumatoid arthritis [14]. Recent studies have high-
lighted the role of the immune system in the pathogen-
esis of this disease [15]. As early as 1988, it was noted
that aberrant expressions of immune mediators such as
cytokines may contribute to the onset of disease symp-
toms [16]. However, reports on changes in serum cyto-
kine levels in FM patients have revealed conflicting
results [17,18]. To uncover direct evidence of the imbal-
ance in cytokine production and secretion in FM
patients we evaluated the cytokine-producing activity of
immune cells in FM patients. We measured plasma cyto-
kine levels in a group of 110 patients with a diagnosis of
FM and we determined responses to mitogen challenges
of their peripheral blood mononuclear cells (PBMC).
The cytokine levels of these patients were compared with
those in a group of 91 matched healthy controls.
Methods
Study groups
This study was approved by the University of Illinois at
Chicago, College of Medicine Institutional Review Board
and all participants consented to participate in this
study. The study was performed in a blinded manner. A
total of 110 fibromyalgia patients and 91 control subjects
were recruited. Patient characteristics are shown in
Table 1. All patients had fibromyalgia symptoms and
had been diagnosed with fibromyalgia for at least one
year. Patients underwent two separate and independent
physical examinations to confirm that they met the cri-
teria according to the current standards of the American
College of Rheumatology [1]. All fibromyalgia patients
had been off FDA-approved fibromyalgia drugs (milnaci-
pran, pregabalin, duloxetine) for at least two weeks.
Patients with any other potentially confounding variables
were excluded, i.e., if they had any other rheumatologic
disorders, any autoimmune or immunologic diseases,
any inflammatory disorder, any infectious disorder or
any neoplastic disorder or were receiving anti-cancer
treatment or had been taking medications affecting the
immune system, including any anti-inflammatory medi-
cations. Matched control subjects lacked a history of any
type of chronic or acute illnesses and none were using
any medications, OTC or prescription drugs that had
any known immunologic effects. They ranged in age
from 18 years to 76 years. The median age was 39 years,
and the average age was 40 years. Of the 91 control sub-
jects, 87 were Caucasian.
Isolation of PBMC
Twenty eight (28) mL of blood were obtained from
patients and healthy volunteers after obtaining theirconsent for research. Blood was withdrawn in four 7 mL
tubes containing 0.081 mL of 15% K3 EDTA solution
(BD VacutainerW, BD, Franklin Lakes, NJ) by
venipuncture. The samples were coded and shipped to
the processing lab in insulated containers at room
temperature. Once received, the blood was transferred
to a 50ml tube, mixed, split in two 50 ml tubes and
diluted 1:1 in GIBCOW Hank’s balanced salt solution
(HBSS, Invitrogen, Carlsbad, CA). The resulting suspen-
sion was layered on top of 15 ml Ficoll (HistopaqueW-
1077, Sigma-Aldrich, St. Louis, MO) in 50 mL tubes and
centrifuged at 700g for 20 minutes. The layer containing
PMBC was harvested and transferred into a new 50 mL
tube. The tube was filled with HBSS and the contents
were mixed by gentle rocking. Cells were collected by
centrifugation at 850g for 10 minutes and resuspended
in 10 mL complete RPMI-1640 medium supplemented
with 10% fetal bovine serum, 1% penicillin-streptomycin
mixture and 1% L-glutamine solution (Invitrogen,
Carlsbad, CA).
PBMC culture
Cells were suspended at a concentration of 10 [6] cells/
mL in a supplemented complete RPMI medium. A 3 mL
suspension was placed in six-well tissue culture plates
Table 2 Concentrations of cytokines in plasma of FM
patients and controls
Cytokine Controls Patients P-value
N Mean SD N Mean SD
MCP-1 65 25 19 95 23 23 0.5681
IL-5 30 24.0 86.0 26 28 103 0.8685
IL-6 39 23 59 47 18 29 0.6511
IL-8 62 22 13 43 25 49 0.7031
IL-10 59 125 713 54 18 41 0.2531
IFN-γ 54 659 1935 51 681 766 0.9383
MIP-1α 36 6 7 24 9 24 0.6807
MIP-1β 87 61 31 107 52 49 0.1506
Concentrations of cytokines in pg/ml are shown.
N, number of subjects whose cytokine values within the detection ranges.
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μg/mL PHA-P (Sigma-AldrichW, St. Louis, MO) or a
mixture of 1 μg/mL phorbol-12-myristate-13-acetate
(PMA) and 1 μg/mL ionomycin (EMD Biosciences, Inc,
Darmstadt, Germany) was added to the wells in tripli-
cate. No chemicals were added to three control plates
which were used to determine the basal levels of expres-
sion. Plates were incubated in a CO2 water jacketed in-
cubator (Forma Scientific, Marjetta, OH) for 18 hours.
Cytokine assay
After overnight culture of PBMC in medium alone
or in the presence of mitogens, 1 mL supernatant
was removed from each plate, centrifuged at 16,000g at
+4°C, for 10 minutes and clear cell-free culture samples
were collected, placed in a new 1.7 mL tube and frozen
at -80°C. Cytokine and chemokine concentrations in
plasma as well as in culture supernatants were deter-
mined using a multiplex immunoassay based on the
Luminex xMAP™ bead array technology. A custom panel
of antibody-conjugated beads for measuring eight
human cytokines (IL-5, IL-6, IL-8, IFN-γ, IL-10, MIP-1α,
MIP-1β, MCP-1) (BioRad Laboratories, Hercules, CA)
was used in the assay according to the manufacturer's
instructions. Cytokine concentrations were determined
in both undiluted and diluted samples. Blank medium
was used as a negative control. Serial dilutions of cyto-
kine standards were run in duplicates in each assay; their
readings were used for calculating standard curves. In
addition, pooled culture supernatants obtained from
activated cells served as a positive control. Fluorescence
was measured with a Bio-Plex 200 fluorescence bead
reader (BioRad Laboratories, Hercules, CA).
Statistical analysis
Fluorescence intensities were transferred into R [19] for
converting to concentration values. The standard curves
were fitted using the 4-parameter logistic (4-PL) or, in
cases when the 4-PL model failed, the 5-parameter logis-
tic (5-PL) model [20]. In total, 192 (24 plates times
8 cytokines) standard curves were fitted. The concen-
trations of cytokines in the plasma of controls and
FM patients were compared using an unpaired two-
sided t-test with unequal variance. This same test was
used to compare the concentrations of cytokines in
unstimulated and stimulated PBMC cultures of controls.
The variances and means of the cytokine concentrations
in patients and healthy individuals were compared using
the F-test and t-test, respectively. The differences in vari-
ance were not detected at α=0.1, except for IL-5 in the
PHA challenge. The descriptive statistics of the groups
as well as the P-values of the latter t-test were also cal-
culated. In order to determine whether the cytokine
concentrations after PHA or PMA stimulations changedin the same direction for each individual patient, we cal-
culated the pair-wise correlations between the cytokines
using Spearman's rank correlation test. For all of the
statistical tests, we used the stats package for R [19].
Results
Concentrations of cytokines in plasma of FM patients
Concentrations of eight cytokines, IFN-γ, IL-5, IL-6,
IL-8, IL-10, MIP-1β, MCP-1, and MIP1-α were measured
in the plasma of the 110 FM patients and the 91 control
subjects (Table 2). The levels of most cytokines were
below the lower limits of detection. When cytokine
levels in FM samples were compared with the control
values, no statistically significant differences were found
at α=0.05.
Levels of cytokines in stimulated PBMC cultures
To determine if cytokine production by immune cells is
altered in FM patients, we measured cellular responses
to the mitogenic activators, phytohemagglutinin (PHA)
and phorbol-12-myristate-13-acetate (PMA) in combin-
ation with ionomycin. PHA, a lectin from Phaseolus vul-
garis (red kidney bean), induces PBMC proliferation as
well as the secretion of cytokines [21,22]. PMA and
ionomycin also stimulate PBMC and activate extracellu-
lar expressions of cytokines [23-25]. We therefore cul-
tured PBMC which were isolated from the blood
samples from the 110 patients and the 91 control sub-
jects in the presence of either PHA or PMA/ionomycin
and determined the concentrations of eight cytokines in
culture supernatants. As shown in Table 3, unstimulated
PBMC cultures produced low levels of cytokines in the
control subjects. Of these 91 tested samples, about half
were below the lower detection limits. In contrast, in
both of the PHA and PMA/ionomycin challenges, extra-
cellular expressions of all cytokines were significantly
increased, resulting in increased cytokine levels in the
Table 3 Concentrations of cytokines in stimulated PBMC cultures of controls
Cytokine Median detection ranges Unstimulated PHA-stimulated PMA/Ionomycin-stimulated
N Mean SD N Mean SD P-value N Mean SD P-value
MCP-1 3-14,000 50 299 217 90 3497 4384 <.001 91 1224 1126 <.001
IL-5 1-13,000 16 2.6 1.3 32 48 150 0.10 87 64 64 <.001
IL-6 1-33,000 59 215 380 91 2799 4182 <.001 91 532 474 <.001
IL-8 2-60,000 56 771 659 89 17456 24246 <.001 90 17607 10103 <.001
IL-10 2-63,000 44 23 29 65 80 94 <.001 87 63 60 <.001
IFN-γ 5-224,000 40 538 338 70 1516 2425 0.001 91 36726 55772 <.001
MIP-1α 1-7,000 56 33 73 91 1084 1773 <.001 90 1246 1051 <.001
MIP-1β 5-14,000 57 222 174 83 4413 5228 <.001 80 6389 4915 <.001
Concentrations of cytokines in pg/ml are shown.
N, number of subjects whose cytokine values were within the detection ranges.
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crease was not statistically significant.
PBMC responses to mitogens in FM patients versus
controls
When cytokine concentrations in patient samples were
compared to the control values, the concentrations of
most cytokines were lower in FM samples (Table 4). The
decrease was statistically significant for all cytokinesTable 4 Cytokine production in response to stimulation in FM
Cytokine
Controls
N Mean SD Min. Max. Med. N
MCP-1 90 3497 4384 69 >OOR 1823 109
IL-5 32 47.7 150.1 <OOR 853 14.1 48
IL-6 91 2799 4182 1.2 15592 273 110
IL-8 89 17456 24246 161 >OOR 4933 110
IL-10 65 80 94 <OOR 352 38 103
IFNγ 70 1516 2425 <OOR 16902 670 101
MIP-1α 91 1084 1773 1.9 9159 240 110
MIP-1β 83 4413 5228 122 >OOR 2282 109
Cytokine PM
Controls
N Mean SD Min. Max. Med. N
MCP-1 91 1224 1126 150 8295 874 108
IL-5 87 63.8 63.9 <OOR 374.5 42.5 98
IL-6 91 532 474 26 2108 350 108
IL-8 90 17607 10103 5724 >OOR 13677 109
IL-10 87 63 60 <OOR 254 40 90
IFNγ 91 36726 55772 205 339591 16130 103
MIP-1α 90 1246 1051 105 >OOR 987 109
MIP-1β 80 6389 4915 254 >OOR 5177 106
Concentrations of cytokines in pg/ml are shown.
N, number of subjects whose cytokine values were within the detection ranges.
OOR, out of range.except for IL-5 in the PHA challenge. Besides muscle
tenderness, the vast majority of the FM patients suffered
from chronic fatigue, sleep disorders as well as mental
fogginess, which is consistent with the universally recog-
nized traits that make up the FM syndrome. Therefore,
the samples from the subgroup of patients having the
same individual traits had a nearly identical change in
cytokine values when compared to the whole group (not





Mean SD Min. Max. Med.
1968 1993 86 >OOR 1310 1.8 0.003
7 17 <OOR 89 1.5 7 0.136
276 437 3.1 2255 108 10.2 <.001
5751 6123 135 37981 3144 3 <.001
12 15 <OOR 84 6.8 6.5 <.001
569 1920 <OOR 15318 124 2.7 0.007
204 272 5.7 1598 109 5.3 <.001





Mean SD Min. Max. Med.
436 421 <OOR 2363 292 2.8 <.001
36 54 <OOR 441 17 1.8 0.002
242 301 <OOR 1509 109 2.2 <.001
8756 6416 215 >OOR 7503 2 <.001
27 37 <OOR 230 11 2.4 <.001
14584 23047 <OOR 144516 5636 2.5 0.001
308 294 <OOR 1551 191 4 <.001
3086 4040 9.5 >OOR 1517 2.1 <.001
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analysis was performed on the patients excluding those
who had a confirmed diagnosis of depression and it
showed similar results (not shown), thereby proving that
depression by itself had an extremely limited impact on
the cytokine profiles in FM patients.
In order to better understand the dynamics of changes
in individual cytokines in patients, we questioned
whether expressions of different cytokines changed simi-
larly in the same samples. We calculated pair-wise corre-
lations between the cytokine concentrations using
Spearman's rank correlation (Table 5). All of the cyto-
kines showed moderate to strong correlations with each
other with a correlation coefficient ρ > 0.4 (all correla-
tions were significant at 1% FDR), suggesting that cyto-
kine dynamics after each treatment is similar in
individual patients. No negative correlations were
observed, which means that no two cytokine expressions
changed in opposite directions.
Discussion
We utilized multiple immunologic methods to develop
an objective test that offers an adjunct to the current
subjective physical findings which are used to make a
diagnosis when a patient is suspected of having FM. This
test is based on specific abnormalities in the cytokine
levels of stimulated peripheral blood mononuclear cells
of such patients. Decreased PBMC responses to chal-
lenges regarding IFN-γ, IL-5, IL-6, IL-8, IL-10, MIP-1β,
MCP-1 and MIP1-α but not IL-5 were statisticallyTable 5 Spearman correlation coefficients of cytokine
expressions in patients
PHA MCP-1 IL-5 IL-6 IL-8 IL-10 IFNγ MIP-1α MIP-1β
MCP-1 1 0.52 0.68 0.80 0.69 0.41 0.61 0.71
IL-5 1 0.67 0.68 0.69 0.65 0.76 0.66
IL-6 1 0.82 0.82 0.76 0.90 0.80
IL-8 1 0.74 0.67 0.84 0.71
IL-10 1 0.57 0.85 0.82
IFNγ 1 0.78 0.55
MIP-1α 1 0.82
MIP-1β 1
PMA MCP-1 IL-5 IL-6 IL-8 IL-10 IFNγ MIP-1α MIP-1β
MCP-1 1 0.60 0.64 0.77 0.52 0.49 0.67 0.51
IL-5 1 0.74 0.48 0.67 0.72 0.71 0.69
IL-6 1 0.57 0.83 0.83 0.88 0.83
IL-8 1 0.48 0.39 0.63 0.43
IL-10 1 0.86 0.86 0.85
IFNγ 1 0.85 0.93
MIP-1α 1 0.87
MIP-1β 1
All Spearman correlation coefficients were significant at 1% FDR.significantly associated with this disorder in a large num-
ber of patients with FM. Decreased expressions of IL-6,
IL-10, and IFN-γ were also observed for purified protein
derivative-stimulated PBMC in patients with Sjogren’s
syndrome with myalgia [26]. The fibromyalgia-related
cytokine patterns which were identified may lend some
insight as to why there has been an overlap in the diag-
noses of mental depression and chronic pain in these
individuals. Chronically depressed patients are charac-
terized by higher pro-inflammatory cytokine blood
levels and lower anti-inflammatory cytokine levels in
blood, similar to what has been found in patients
with chronic pain [27-31]. Decreased IL-10, IL-1α and
IFN-γ production by mitogen-stimulated PBMC was
observed in depressed patients which correlated with
our findings [32,33].
The methodology used in this study differs signifi-
cantly from previous studies; therefore the findings of
this study cannot be directly compared to the results of
previous studies of cytokines in patients with FM. For
example, many studies examined levels of cytokines in
serum or plasma, used different controls or did not en-
sure that their patients were not receiving treatments for
FM [17,18]. Our findings prove that relying on a meth-
odology that solely measures circulating cytokine levels
leads to results that are statistically insignificant and
such measurements fail to confer any diagnostic values.
There have been several studies which employed iso-
lated peripheral blood cells which were stimulated with
different agents and they measured levels of a limited
number of cytokines after stimulation [34-37]. The latter
studies further differed from the methods used in this
study regarding the types of PBMCs used (e.g., whole
blood, isolated lymphocytes and monocytes alone or to-
gether) and in the methods of measurement (e.g., ELISA,
flow cytometry, intracellular cytokine staining, and RT-
PCR). Regardless of the methodology used, our study
revealed significant differences in cytokine expressions
in PBMCs from FM patients versus control cells, which
can be utilized as the basis of a clinical diagnostic test
for FM.
The common thread in these studies as related to the
current study was a reduction or no increase in the
levels of cytokines IL-6, IL-8, IL-10 and IFN-γ in
patients with chronic pain.
The fibromyalgia syndrome by definition lacks any
consistent patterns regarding pain intensity, which is a
totally subjective process. Pain duration is a required cri-
teria per the American College of Rheumatology defin-
ition for the diagnosis of FM, which we adhered to. In
the past, FM was claimed to be a rheumatologic, neuro-
logic or psychiatric disease despite the fact that there
were no objective links to any of those pathways. Our
findings uncovered evidence that FM is instead an
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basis of FM occurs independently of any subjective fea-
tures. Hence, this illustrates the very strong clinical value
of our test protocol. The fact that individual cytokines
exhibited similar dynamics in patient samples reveals
that the FM patients are uniform in regard to their cellu-
lar immunologic responses.Conclusion
We conclude that the aberrant responses of levels of a
large number of cytokines of in vitro stimulated PBMC
using the methodology in this study is significantly cor-
related with the clinical diagnosis of FM. This method-
ology provides a useful confirmation of the clinical
diagnosis of FM. Further, this method of evaluating cyto-
kines levels in stimulated PBMC may prove useful in
analyzing specific responses to therapeutic modalities
and medications in order to determine the efficacy of
such interventions.
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